Cell Death & Disease-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤 经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;细胞死亡 经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞 经验分享：1/11 投稿還沒有editor assigned，祝大家投稿順利來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡 经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述，一直是Under Consideration，在第22天左右分配了编辑，然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ，等待中。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗？从提交文章到有结果大概是什么流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=)]

2023-04-06 123f51aam86(暂无昵称) 来自陕西省

审稿速度:3.0 | 投稿命中率:50.0
经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~

158 23

展开23条回复

[GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤 经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;细胞死亡 经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞 经验分享：1/11 投稿還沒有editor assigned，祝大家投稿順利來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡 经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述，一直是Under Consideration，在第22天左右分配了编辑，然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ，等待中。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗？从提交文章到有结果大概是什么流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=)]

2024-03-25 124a8810m95(暂无昵称) 来自重庆

偏重的研究方向：肿瘤
经验分享：小cdd好还是cancer letters好？

20 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤 经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;细胞死亡 经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞 经验分享：1/11 投稿還沒有editor assigned，祝大家投稿順利來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡 经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述，一直是Under Consideration，在第22天左右分配了编辑，然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ，等待中。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗？从提交文章到有结果大概是什么流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=)]

2023-08-25 1245a556m23暂无昵称来自河南省

从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？

75 17

展开17条回复

[GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤 经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;细胞死亡 经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞 经验分享：1/11 投稿還沒有editor assigned，祝大家投稿順利來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡 经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述，一直是Under Consideration，在第22天左右分配了编辑，然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ，等待中。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗？从提交文章到有结果大概是什么流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=)]

2024-01-16 ms4000000731438466 来自天津

偏重的研究方向：肿瘤
经验分享：提交10天，显示状态为Decision made什么情况？

43 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤 经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;细胞死亡 经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞 经验分享：1/11 投稿還沒有editor assigned，祝大家投稿順利來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡 经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述，一直是Under Consideration，在第22天左右分配了编辑，然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ，等待中。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗？从提交文章到有结果大概是什么流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=)]

2023-05-18 36192448 来自湖南省

偏重的研究方向：细胞死亡
经验分享：一审65天了，还没消息，彻底躺平了

80 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤 经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;细胞死亡 经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞 经验分享：1/11 投稿還沒有editor assigned，祝大家投稿順利來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡 经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述，一直是Under Consideration，在第22天左右分配了编辑，然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ，等待中。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗？从提交文章到有结果大概是什么流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=)]

2023-07-07 36192448 来自湖南省

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：干细胞;细胞死亡
经验分享：一审84天，二审7天，目前decision made 7天还没消息

83 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤 经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;细胞死亡 经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞 经验分享：1/11 投稿還沒有editor assigned，祝大家投稿順利來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡 经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述，一直是Under Consideration，在第22天左右分配了编辑，然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ，等待中。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗？从提交文章到有结果大概是什么流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=)]

2024-02-06 ms3000001660419742 来自台湾省

偏重的研究方向：幹細胞
经验分享：1/11 投稿還沒有editor assigned，祝大家投稿順利來沾沾大家的喜氣QQ

35 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤 经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;细胞死亡 经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞 经验分享：1/11 投稿還沒有editor assigned，祝大家投稿順利來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡 经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述，一直是Under Consideration，在第22天左右分配了编辑，然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ，等待中。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗？从提交文章到有结果大概是什么流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=)]

2023-07-01 Shawnwang 来自广东省

偏重的研究方向：细胞死亡
经验分享：刚刚submit，上帝保佑，沾沾大家的喜气

136 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤 经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;细胞死亡 经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞 经验分享：1/11 投稿還沒有editor assigned，祝大家投稿順利來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡 经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述，一直是Under Consideration，在第22天左右分配了编辑，然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ，等待中。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗？从提交文章到有结果大概是什么流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=)]

2024-03-05 超超不吵吵来自湖南省

投了一篇综述，一直是Under Consideration，在第22天左右分配了编辑，然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ，等待中。

24 0

[GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤 经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;细胞死亡 经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞 经验分享：1/11 投稿還沒有editor assigned，祝大家投稿順利來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡 经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述，一直是Under Consideration，在第22天左右分配了编辑，然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ，等待中。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗？从提交文章到有结果大概是什么流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=)]

2022-10-02 ms4000000661887175

请问有投综述的吗？从提交文章到有结果大概是什么流程？

48 3

展开3条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务